- Condition: Glioblastoma
Interventions: Drug: Hydroxychloroquine; Radiation: Radiotherapy
Sponsors: University College, London; University College, London; Cancer Research UK
Not yet recruiting - verified May 2012 - Condition: Newly Diagnosed Glioblastoma Multiforme
Intervention: Other: Lapatinib/Temozolomide/radiation
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Meningioma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Choroid Plexus Tumor; Adult Craniopharyngioma; Adult Diffuse Astrocytoma; Adult Ependymoblastoma; Adult Ependymoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Grade I Meningioma; Adult Grade II Meningioma; Adult Medulloblastoma; Adult Meningeal Hemangiopericytoma; Adult Mixed Glioma; Adult Myxopapillary Ependymoma; Adult Oligodendroglioma; Adult Papillary Meningioma; Adult Pilocytic Astrocytoma; Adult Pineal Gland Astrocytoma; Adult Pineoblastoma; Adult Pineocytoma; Adult Subependymal Giant Cell Astrocytoma; Adult Subependymoma; Adult Supratentorial Primitive Neuroectodermal Tumor (PNET); Meningeal Melanocytoma; Nonmalignant Neoplasm; Recurrent Adult Brain Tumor; Tumors Metastatic to Brain
Interventions: Drug: pioglitazone hydrochloride; Other: laboratory biomarker analysis; Radiation: external beam radiation therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Procedure: management of therapy complications
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Glioblastoma
Interventions: Drug: LY2157299 monohydrate; Drug: Lomustine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Brain Tumor; Recurring Glioblastoma
Intervention: Biological: delta-24-RGD adenovirus
Sponsors: Erasmus Medical Center; Erasmus Medical Center; VU University Medical Center
Recruiting - verified April 2012 - Conditions: Brain Neoplasms; Central Nervous System Neoplasms
Interventions: Drug: TPI287; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Archer Biosciences, Inc.
Not yet recruiting - verified April 2012 - Condition: Glioblastoma Multiforme
Interventions: Drug: Lucanthone; Drug: Temozolomide (TMZ); Radiation: Radiation; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified April 2012 - Conditions: Dose Escalation; Safety; Preliminary Efficacy; Advanced Solid Tumors; Metastatic Breast Cancer; Advanced Pancreatic Adenocarcinoma; Metastatic Colorectal Cancer; Recurrent Glioblastoma Multiforme
Intervention: Drug: LDE225 and BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Conditions: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
Interventions: Drug: aminolevulinic acid; Procedure: therapeutic conventional surgery
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012 - Conditions: Glioma; Glioblastoma Multiforme; Neoplasms
Interventions: Procedure: Surgery; Drug: Chemotherapy; Radiation: Radiotherapy; Biological: DC vaccination; Drug: blank placebo
Sponsors: Huashan Hospital; Huashan Hospital; Fudan University
Recruiting - verified March 2012 - Conditions: Glioblastoma; Glioblastoma Multiforme
Intervention: Biological: Chimeric monoclonal antibody (TRC105) to CD105
Sponsors: Tracon Pharmaceuticals Inc.; Tracon Pharmaceuticals Inc.
Not yet recruiting - verified May 2012 - Condition: Recurrent Glioblastoma
Intervention: Drug: axitinib
Sponsors: Universitair Ziekenhuis Brussel; Bart Neyns; Pfizer
Recruiting - verified March 2012 - Conditions: Brain and Central Nervous System Tumors; Neurofibromatosis Type 1
Intervention: Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Supratentorial Newly Diagnosed Inoperable Gliobastoma
Interventions: Drug: Drug (including placebo); Other: Standard therapy
Sponsors: Merck KGaA; Merck KGaA
Not yet recruiting - verified March 2012 - Condition: Glioblastoma, Glioma
Intervention: Drug: GDC-0084
Sponsors: Genentech; Genentech
Recruiting - verified May 2012 - Conditions: Brain and Central Nervous System Tumors; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: trebananib; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: dynamic contrast-enhanced magnetic resonance imaging
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Malignant Gliomas
Interventions: Device: DECT; Device: MR spectroscopy
Sponsors: London Health Sciences Centre; London Health Sciences Centre; University of Western Ontario, Canada; London Regional Cancer Program, Canada
Recruiting - verified March 2012 - Conditions: Glioblastoma Multiforme; Brain Metastases
Interventions: Drug: NM404; Drug: NM404
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified March 2012 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsConditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Primary Hepatocellular Carcinoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Hormone-resistant Prostate Cancer; Limited Stage Small Cell Lung Cancer; Localized Resectable Adult Primary Liver Cancer; Male Breast Cancer; Mast Cell Sarcoma; Ovarian Sarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Adult Soft Tissue Sarcoma; Recurrent Bladder Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Esophageal Cancer; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Gastric Cancer; Recurrent Kaposi Sarcoma; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Osteosarcoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Prostate Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Small Intestine Leiomyosarcoma; Stage I Colon Cancer; Stage I Rectal Cancer; Stage I Uterine Sarcoma; Stage IA Breast Cancer; Stage IA Gastric Cancer; Stage IA Ovarian Epithelial Cancer; Stage IA Ovarian Germ Cell Tumor; Stage IB Breast Cancer; Stage IB Gastric Cancer; Stage IB Ovarian Epithelial Cancer; Stage IB Ovarian Germ Cell Tumor; Stage IC Ovarian Epithelial Cancer; Stage IC Ovarian Germ Cell Tumor; Stage II Breast Cancer; Stage II Uterine Sarcoma; Stage IIA Colon Cancer; Stage IIA Gastric Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIA Rectal Cancer; Stage IIB Colon Cancer; Stage IIB Esophageal Cancer; Stage IIB Gastric Cancer; Stage IIB Melanoma; Stage IIB Non-small Cell Lung Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIB Rectal Cancer; Stage IIC Colon Cancer; Stage IIC Melanoma; Stage IIC Ovarian Epithelial Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIC Rectal Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Colon Cancer; Stage IIIA Esophageal Cancer; Stage IIIA Gastric Cancer; Stage IIIA Melanoma; Stage IIIA Non-small Cell Lung Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Rectal Cancer; Stage IIIB Breast Cancer; Stage IIIB Colon Cancer; Stage IIIB Esophageal Cancer; Stage IIIB Gastric Cancer; Stage IIIB Melanoma; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Rectal Cancer; Stage IIIC Breast Cancer; Stage IIIC Colon Cancer; Stage IIIC Esophageal Cancer; Stage IIIC Gastric Cancer; Stage IIIC Melanoma; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Rectal Cancer; Stage IV Bladder Cancer; Stage IV Esophageal Cancer; Stage IV Gastric Cancer; Stage IV Melanoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sirolimus; Other: laboratory biomarker analysis; Biological: DEC-205-NY-ESO-1 fusion protein vaccine
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012 - Condition: Glioblastoma
Intervention: Dietary Supplement: Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)
Sponsors: Michigan State University; Michigan State University; Sparrow Health System
Not yet recruiting - verified February 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Drug: veliparib; Genetic: gene expression analysis; Genetic: protein analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Recurrent Glioblastoma
Intervention: Drug: PF-299804 (Dacomitinib)
Sponsors: Grupo Español de Investigación en Neurooncología; Grupo Español de Investigación en Neurooncología; Pfizer
Recruiting - verified March 2012 - Condition: Gliomas
Interventions: Drug: Cilengitide; Drug: Temozolomide
Sponsors: Martin-Luther-Universität Halle-Wittenberg; Martin-Luther-Universität Halle-Wittenberg; Merck KGaA
Recruiting - verified January 2012 - Conditions: Glioblastoma; Brain Metastases NOS
Intervention: Drug: NM404
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Astrocytoma; Glioma
Intervention: Drug: 5-Aminolevulinic Acid
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified December 2011 - Condition: Glioblastoma Multiforme
Interventions: Drug: Axitinib; Radiation: Radiation Therapy
Sponsors: University of Cincinnati; University of Cincinnati; Pfizer
Recruiting - verified January 2012 - Conditions: Brain Cancer; Brain Stem Glioma
Intervention: Radiation: Radioactive iodine-labeled monoclonal antibody 8H9
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University; Johns Hopkins University School of Medicine (Data analysis only)
Recruiting - verified March 2012 - Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component; Recurrent Glioblastoma; Relapsed Glioblastoma
Interventions: Drug: Bevacizumab; Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012 - Condition: Glioblastoma
Interventions: Drug: Phase 1 Dose Escalation; Drug: Phase 1b; Drug: Ancillary Study
Sponsors: Actelion; Actelion
Recruiting - verified December 2011 - Condition: Glioblastoma
Interventions: Radiation: Radiotherapy; Radiation: Experimental arm
Sponsors: Institut Claudius Regaud; Institut Claudius Regaud
Recruiting - verified January 2012 - Condition: Glioblastoma
Intervention:
Sponsors: University of Nebraska; University of Nebraska
Recruiting - verified December 2011 - Conditions: Recurrent Supratentorial Glioblastoma Multiforme; GBM; Glioblastoma Multiforme
Intervention: Biological: Live attenuated, oral (Sabin) serotype 1 poliovirus vaccine (PVSRIPO)
Sponsors: Duke University; Duke University; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: mibefradil dihydrochloride; Drug: temozolomide; Other: 3'-deoxy-3'-[18F]fluorothymidine; Other: pharmacological study
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI); Tau Therapeutics LLC
Recruiting - verified April 2012 - Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma
Intervention: Biological: Toca 511
Sponsors: Tocagen Inc.; Tocagen Inc.
Recruiting - verified January 2012 - Conditions: Glioma; Glioblastoma; Glioblastoma Multiforme; GBM; Brain Cancer
Intervention: Drug: VAL-083
Sponsors: Del Mar Pharmaceuticals (BC), LTD; Del Mar Pharmaceuticals (BC), LTD
Recruiting - verified April 2012 - Condition: Glioblastoma Multiforme
Interventions: Drug: bevacizumab; Drug: fotemustine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Glioblastoma Multiforme
Intervention: Drug: Avastin
Sponsors: Brain & Spine Surgeons of New York; Brain & Spine Surgeons of New York
Recruiting - verified February 2012 - Conditions: Glioblastoma Multiforme; Gliosarcoma; Anaplastic Astrocyloma; Oligoastrocytoma; Malignant Glioma
Intervention: Drug: AZD7451
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Brain Cancer
Intervention: Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011 - Condition: Glioblastoma Multiforme
Interventions: Radiation: Low Dose Fractionated Radiation Therapy (LDFRT); Drug: Temozolomide
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified April 2012 - Condition: Glioblastoma Multiforme
Interventions: Radiation: Radiation; Drug: Chemotherapy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012 - Conditions: Glioblastoma; GBM; Glioma; High Grade Glioma
Intervention: Drug: Trans Sodium Crocetinate (TSC)
Sponsors: Diffusion Pharmaceuticals LLC; Diffusion Pharmaceuticals LLC
Recruiting - verified April 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: sunitinib malate; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Recurrent Glioblastoma Multiforme
Interventions: Radiation: Stereotactic hypofractionated RT 5x5Gy; Radiation: Stereotactic hypofractionated RT 5x7Gy
Sponsors: University of Sao Paulo; Andre Tsin Chih Chen
Recruiting - verified October 2011 - Conditions: Advanced Malignant Glioma; Anaplastic Astrocytomas; Glioblastoma Multiforme
Intervention: Drug: AMG 595
Sponsors: Amgen; Amgen
Not yet recruiting - verified November 2011 - Condition: Glioblastoma Multiforme
Interventions: Radiation: Radiotherapy; Radiation: Radiotherapy
Sponsors: International Atomic Energy Agency; International Atomic Energy Agency; Fundación Escuela de Medicina Nuclear; N.N. Alexandrov National Cancer Centre of Belarus; Hospital A.C. Camargo; Irmandade Santa Casa de Misericórdia de Porto Alegre; Instituto de Radiomedicina (IRAM); Postgraduate Institute of Medical Education and Research; Cipto Mangunkusumo General Hospital; Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology; Chiang Mai University; Institut National de Cancer Salah Azaiz; Wilson Roa Professional Corporation; All Ireland Cooperative Oncology Research Group; Ege University; High Technology Medical Center
Recruiting - verified December 2011 - Conditions: Malignant Glioma; Glioblastoma; Brain Cancer
Interventions: Genetic: Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL; Drug: Aldesleukin; Drug: Fludarabine; Drug: Cyclophosphamide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Benign Neoplasms, Brain; Brain Cancer; Brain Neoplasms, Benign; Brain Neoplasms, Malignant; Brain Tumor, Primary; Brain Tumor, Recurrent; Brain Tumors; Intracranial Neoplasms; Neoplasms, Brain; Neoplasms, Intracranial; Primary Brain Neoplasms; Primary Malignant Brain Neoplasms; Primary Malignant Brain Tumors; Gliomas; Glioblastoma
Intervention: Drug: 5-ALA (Gliolan)
Sponsors: Emory University; Emory University
Recruiting - verified April 2012 - Condition: Glioblastoma Multiforme
Intervention: Drug: Temozolomide, bevacizumab and bortezomib
Sponsors: Emory University; Emory University
Recruiting - verified March 2012 - Conditions: Brain Neoplasms; Central Nervous System Neoplasms
Interventions: Drug: Everolimus; Drug: Sorafenib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bayer; Novartis
Not yet recruiting - verified February 2012 - Condition: Brain Cancer
Interventions: Drug: Temozolomide; Drug: Memantine; Drug: Mefloquine; Drug: Metformin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012 - Condition: Advanced Solid Tumors
Interventions: Drug: E7050 plus E7080; Drug: E7080 plus E7050; Drug: E7050 plus E7080 or E7080 alone plus E7050 add-on therapy; Drug: E7050 plus E7080; Drug: E7050
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified March 2012 - Condition: Glioblastoma
Interventions: Drug: BKM120 + temozolomide; Drug: BKM120 +temozolomide with/without radiotherapy
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Glioblastoma
Interventions: Drug: Bevacizumab; Radiation: Radiation therapy
Sponsors: University of Zurich; University of Zurich
Recruiting - verified April 2012 - Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Seizure
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: cognitive assessment; Procedure: contrast-enhanced magnetic resonance imaging; Procedure: magnetic resonance imaging; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified October 2011 - Conditions: Glioblastoma; Brain Neoplasm
Intervention: Procedure: Craniotomy
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified April 2012 - Condition: HIGH GRADE GLIOMA
Interventions: Drug: TH-302; Drug: Placebo
Sponsors: Threshold Pharmaceuticals; Threshold Pharmaceuticals; The University of Texas Health Science Center at San Antonio
Recruiting - verified July 2011 - Condition: Glioma
Intervention: Drug: 5-Aminolevuline Acid
Sponsors: Legacy Health System; Legacy Health System; DUSA Pharmaceuticals, Inc.
Recruiting - verified July 2011 - Condition: Glioblastoma
Interventions: Drug: Cyclophosphamide; Biological: IMA950 plus GM-CSF; Biological: IMA950; Drug: Imiquimod
Sponsors: immatics Biotechnologies GmbH; immatics Biotechnologies GmbH; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Brain Cancer; MALIGNANT GLIOMA; Glioblastoma; Anaplastic Astrocytoma (AA); Anaplastic Oligodendroglioma (AO); Anaplastic Oligo-astrocytoma (AOA); Anaplastic Mixed Gliomas; Malignant Glioma NOS
Intervention: Other: Bevacizumab & stereotactic radiotherapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech; Columbia University; University of California, San Francisco
Recruiting - verified April 2012 - Condition: Diffuse Intrinsic Pontine Glioma
Interventions: Biological: Brain tumor initiating cells; Drug: Imiquimod
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Not yet recruiting - verified March 2012 - Conditions: Optic Glioma; Pilocytic Astrocytoma; Low Grade Glioma; Fibriullary Astrocytoma
Intervention: Drug: AZD6244
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Diffuse Intrinsic Pontine Glioma; Progressive or Refractory High-Grade Glioma
Interventions: Drug: Crenolanib; Drug: Crenolanib
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Arog Pharmaceuticals LLC
Recruiting - verified January 2012 - Conditions: Glioblastoma Multiforme; Anaplastic Glioma
Interventions: Drug: PPX (CT2103); Drug: Temozolomide
Sponsors: Brown University; Debora G. Isdale; Yale University; Milton S. Hershey Medical Center; University of Washington; University of Massachusetts, Worcester; Maine Medical Center
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: olaparib; Drug: temozolomide; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: diffusion-weighted magnetic resonance imaging; Procedure: dynamic contrast-enhanced magnetic resonance imaging; Procedure: therapeutic conventional surgery
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified April 2012 - Conditions: Prostate Cancer; Pancreatic Cancer; Melanoma; Renal Cell Carcinoma; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Bladder Cancer; Non-small Cell Lung Cancer; Glioblastoma
Intervention: Biological: MGA271
Sponsors: MacroGenics; MacroGenics
Recruiting - verified December 2011 - Conditions: Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma
Intervention: Drug: BIBF 1120
Sponsors: Dana-Farber Cancer Institute; Patrick Y. Wen, MD; Boehringer Ingelheim Pharmaceuticals; Wake Forest University Baptist Medical Center; Dartmouth-Hitchcock Medical Center; University of Virginia; Massachusetts General Hospital
Not yet recruiting - verified December 2011 - Conditions: Renal Cell Carcinoma; Soft Tissue Sarcoma; Glioblastoma; Ovarian Cancer; Cervical Cancer; Breast Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Pancreatic Cancer; Melanoma; Gastrointestinal Cancer
Intervention: Drug: Pazopanib
Sponsors: Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; GlaxoSmithKline; Cambridge Experimental Cancer Medicine Centre
Recruiting - verified June 2011 - Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma
Interventions: Drug: Bevacizumab and Carboplatin; Drug: Bevacizumab and Carboplatin
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified December 2011 - Conditions: Breast Cancer; Non-Small-Cell Lung Cancer; Glioblastoma; Other Cancers
Intervention: Drug: FPPRGD2
Sponsors: Stanford University; Stanford University
Recruiting - verified February 2012 - Conditions: Low Grade Gliomas; Protoplasmic Astrocytomas; Fibrillary Astrocytomas; Gemistocytic Astrocytomas; Oligoastrocytomas; Oligodendrogliomas; Other WHO Grade II/IV Gliomas
Intervention: Radiation: Proton radiation
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Multiple Myeloma; Non-Hodgkin's Lymphoma; Glioblastoma Multiforme; Head and Neck Squamous Cell Cancer; Triple Negative Breast Cancer; Hormone Receptor-Positive Breast Cancer; Castration-Resistant Prostate Cancer; Ewing's Family of Sarcomas
Intervention: Drug: CC-115
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Condition: Recurrent Glioblastoma
Intervention: Drug: PLX3397
Sponsors: Plexxikon; Plexxikon
Recruiting - verified May 2012 - Conditions: Brain and Central Nervous System Tumors; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Procedure: acupressure therapy; Procedure: sham intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Brain and Central Nervous System Tumors; Depression
Interventions: Drug: temozolomide; Drug: vorinostat; Other: survey administration; Procedure: magnetic resonance spectroscopic imaging
Sponsors: National Cancer Institute (NCI); Winship Cancer Institute of Emory University; National Cancer Institute (NCI)
Recruiting - verified April 2011 - Condition: Glioblastoma Multiforme
Interventions: Drug: Bevacizumab; Drug: BKM120
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Novartis
Recruiting - verified March 2012 - Condition: Glioblastoma
Interventions: Drug: BKM120; Procedure: Surgery
Sponsors: Dana-Farber Cancer Institute; Patrick Y. Wen, MD; Brigham and Women's Hospital; Massachusetts General Hospital; Novartis Pharmaceuticals; M.D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; University of California, San Francisco; University of California, Los Angeles
Recruiting - verified February 2012 - Conditions: Ewing's Sarcoma; Osteosarcoma; Astrocytoma; Atypical Teratoid/Rhabdoid Tumor; Ependymoma; Germ Cell Tumor; Glioma; Medulloblastoma; Rhabdoid Tumor; Retinoblastoma; Clear Cell Sarcoma; Renal Cell Carcinoma; Wilms Tumor; Hepatoblastoma; Neuroblastoma; Rhabdomyosarcoma
Intervention: Drug: sirolimus
Sponsors: Emory University; Emory University; Children's Healthcare of Atlanta
Recruiting - verified October 2011 - Conditions: High Grade Glioma: Glioblastoma (GBM); High Grade Glioma: Gliosarcoma; Anaplastic Astrocytoma (AA); Anaplastic Oligodendroglioma (AO); Mixed Anaplastic Oligoastrocytoma (AOA)
Interventions: Drug: Plerixafor; Drug: Plerixafor; Drug: Bevacizumab; Drug: Plerixafor; Procedure: Surgery
Sponsors: Dana-Farber Cancer Institute; Patrick Y. Wen, MD; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; Genzyme
Recruiting - verified February 2012 - Condition: Glioblastoma
Intervention: Drug: bosutinib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Pfizer
Recruiting - verified April 2012 - Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Malignant Glioma; Brainstem Glioma
Intervention: Drug: AZD8055
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: aminolevulinic acid hydrochloride; Drug: polifeprosan 20 with carmustine implant; Drug: temozolomide; Genetic: gene expression analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer Research UK
Recruiting - verified May 2011 - Condition: Glioblastoma Multiforme
Interventions: Drug: RO5323441 + bevacizumab [Avastin]; Drug: bevacizumab [Avastin]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.Condition: Glioblastoma Multiforme
Intervention: Drug: H-1PV
Sponsors: Oryx GmbH & Co. KG; Oryx GmbH & Co. KG
Recruiting - verified September 2011 - Conditions: Grade IV Glioma; Grade IV Astrocytoma; Glioblastoma Multiforme
Intervention: Biological: TVI-Brain-1
Sponsors: TVAX Biomedical; TVAX Biomedical
Recruiting - verified April 2012 - Conditions: Brain Tumor; Low Grade Glioma; Astrocytoma; Ependymoma; Ganglioglioma
Intervention: Radiation: Proton radiotherapy
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute
Recruiting - verified September 2011 - Conditions: Recurrence of Solid Tumor; Glioblastoma Multiforme; Melanoma
Interventions: Drug: MK-4827; Drug: Temozolomide
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects
Interventions: Biological: bevacizumab; Drug: lomustine; Genetic: DNA methylation analysis; Other: laboratory biomarker analysis; Procedure: cognitive assessment; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Not yet recruiting - verified September 2011 - Conditions: Low Grade Glioma; Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Oligoastrocytoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Glioblastoma Multiforme
Interventions: Biological: ICT-107; Biological: Placebo DC
Sponsors: ImmunoCellular Therapeutics, Ltd.; ImmunoCellular Therapeutics, Ltd.
Recruiting - verified May 2012 - Conditions: Brain and Central Nervous System Tumors; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: imetelstat sodium; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma
Interventions: Drug: Bevacizumab; Drug: Bevacizumab
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012 - Condition: Brain Cancer
Interventions: Drug: Vorinostat; Drug: Bevacizumab; Drug: Bevacizumab; Drug: Vorinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified April 2012 - Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma MultiformeCondition: Relapsed Glioblastoma Multiforme
Intervention: Drug: VB-111
Sponsors: Vascular Biogenics Ltd. operating as VBL Therapeutics; Vascular Biogenics Ltd. operating as VBL Therapeutics
Recruiting - verified November 2011 - Conditions: Glioblastoma Multiforme; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Mixed Oligoastrocytoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Glioblastoma
Intervention: Drug: PX-866
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Oncothyreon Inc.
Recruiting - verified December 2011 - Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Tumor
Interventions: Drug: Montanide ISA-51/survivin peptide vaccine; Biological: sargramostim; Other: flow cytometry; Other: laboratory biomarker analysis; Other: immunoenzyme technique
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Not yet recruiting - verified January 2012 - Conditions: Glioblastoma Multiforme (GBM); ANAPLASTIC ASTROCYTOMA (AOA)
Intervention: Drug: Superselective Intraarterial Cerebral Infusion of Cetuximab
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012 - Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Meningioma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Choroid Plexus Tumor; Adult Diffuse Astrocytoma; Adult Ependymoblastoma; Adult Ependymoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Grade II Meningioma; Adult Medulloblastoma; Adult Meningeal Hemangiopericytoma; Adult Mixed Glioma; Adult Oligodendroglioma; Adult Papillary Meningioma; Adult Pineal Gland Astrocytoma; Adult Pineoblastoma; Adult Pineocytoma; Adult Supratentorial Primitive Neuroectodermal Tumor (PNET); Recurrent Adult Brain Tumor
Interventions: Procedure: yoga therapy; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: boron phenylalanine; Drug: mannitol; Other: biologic sample preservation procedure; Radiation: radiation therapy treatment planning/simulation
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified February 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: lenalidomide; Other: laboratory biomarker analysis; Other: pharmacological study; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); NCI - Pediatric Oncology Branch; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma
Intervention: Drug: PD 0332991
Sponsors: University of California, San Francisco; University of California, San Francisco; Pfizer
Recruiting - verified January 2012 - Conditions: Diffuse Intrinsic Pontine Glioma; Anaplastic Astrocytoma; High Grade Glioma
Interventions: Drug: Lenalidomide; Radiation: Radiation Therapy
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: glioblastoma multiforme multipeptide vaccine IMA950; Biological: sargramostim; Drug: temozolomide; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified April 2012 - Conditions: Glioma; Anaplastic Astrocytoma; Anaplastic Astro-oligodendroglioma; Glioblastoma
Intervention: Biological: autologous tumor lysate-pulsed DC vaccination
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified September 2010 - Conditions: Glioblastoma Multiforme; GBM; Brain Cancer
Intervention: Biological: CMV-specific CTL
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; Center for Cell and Gene Therapy, Baylor College of Medicine; The Methodist Hospital System
Recruiting - verified August 2011 - Conditions: Juvenile Pilcytic Astrocytoma (JPA); Pleomorphic JPA; Diffuse Astrocytoma (Fibrillary, Gemistocytic, Giant Cell, or Pleomorphic Xanthoastrocytoma); Low Grade Oligoastrocytoma; Low Grade Oligodendroglioma; Low Grade Glioma NOS
Intervention: Drug: Poly ICLC
Sponsors: University of California, San Diego; University of California, San Diego; Emory University
Recruiting - verified June 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Not yet recruiting - verified May 2012 - Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma
Intervention: Drug: Super-Selective Intraarterial Intracranial Infusion of Temozolomide
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012 - Conditions: Glioblastoma Multiforme; Gliosarcoma
Intervention: Drug: Gliadel, Radiation Therapy, Avastin, Temodar
Sponsors: Duke University; Duke University; Genentech; Eisai Inc.
Recruiting - verified March 2012 - Condition: Diffuse Intrinsic Pontine Glioma
Interventions: Drug: Bevacizumab; Drug: Erlotinib; Drug: Temozolomide; Radiation: Irradiation
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; University of California, San Francisco; Children's Hospital Boston; Children's Memorial Hospital; Children's Hospital Los Angeles; University of Utah; Memorial Sloan-Kettering Cancer Center; Seattle Children's Hospital; Children's Hospital Colorad; Doernbecher Children's Hospital; Washington University Children's Hospital; Miami Children's Hospital; Johns Hopkins University; University of Florida; Children's Hospitals and Clinics of Minnesota; Southwestern Regional Medical Center; New York University; University of Rochester; University of Mississippi Medical Center; Louisville Children's Hospital; Children's Healthcare of Atlanta
Recruiting - verified September 2011 - Conditions: Adult Anaplastic Astrocytoma; Recurrent Grade III Glioma; Recurrent Grade IV Glioma; Adult Anaplastic Oligodendroglioma; Adult Brain Tumor; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Tumor; Adult Anaplastic Oligoastrocytoma; Recurrent High Grade Glioma
Interventions: Drug: flucytosine; Other: polymerase chain reaction; Other: immunohistochemistry staining method; Biological: gene therapy; Other: pharmacological study; Other: 3-Tesla magnetic resonance imaging; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery; Biological: E. coli CD-expressing genetically modified neural stem cells
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified April 2012 - Conditions: Multiple Myeloma; Diffuse Large B-Cell Lymphoma; Glioblastoma Multiforme; Hepatocellular Carcinoma; Non-Small Cell Lung Cancer; Gastrointestinal Neuroendocrine Tumors of Non-Pancreatic Origin; Hormone Receptor-Positive Breast Cancer
Intervention: Drug: CC-223
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Diffuse Astrocytoma; Adult Ependymoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Myxopapillary Ependymoma; Adult Oligodendroglioma; Adult Pilocytic Astrocytoma; Adult Pineal Gland Astrocytoma; Adult Subependymal Giant Cell Astrocytoma; Adult Subependymoma
Interventions: Procedure: biopsy; Procedure: computed tomography; Procedure: therapeutic conventional surgery; Radiation: radiation therapy treatment planning/simulation; Radiation: radiation therapy; Procedure: magnetic resonance imaging; Procedure: positron emission tomography; Drug: fluorine F 18 fluorodopa
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Glioblastoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma
Interventions: Biological: Toca 511; Drug: 5-FC
Sponsors: Tocagen Inc.; Tocagen Inc.
Recruiting - verified November 2011 - Condition: Glioblastoma Multiforme
Interventions: Drug: Dexamethasone acetate; Drug: Dexamethasone
Sponsors: Duke University; Duke University
Not yet recruiting - verified February 2012 - Conditions: Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Genetic: DNA methylation analysis
Sponsors: University of California, Los Angeles; University of California, Los Angeles; Genentech
Recruiting - verified February 2012 - Condition: Brain Tumors
Intervention: Procedure: fMRI Evaluation
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - Condition: Glioblastoma
Interventions: Drug: Temozolomide and lomustine; Drug: Temozolomide
Sponsors: University Hospital, Bonn; University Hospital, Bonn
Recruiting - verified May 2011 - Conditions: Newly Diagnosed Pediatric Pontine Glioma.; Newly Diagnosed Pediatric High Grade Glioma.; Recurrent Pediatric High Grade Glioma.; Recurrent Pediatric Low Grade Glioma.
Interventions: Biological: HLA-A2 restricted synthetic glioma antigen peptides vaccine; Drug: Poly ICLC; Genetic: Reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Children's Hospital of Pittsburgh; Children's Hospital of Pittsburgh; Stratum A,B and E NCI R21 CA149872; Stratum C-Brain Tumor Society; Stratum D- P01NS40923
Recruiting - verified May 2010 - Conditions: Glioblastoma Multiforme; Controls (Those Without Glioblastoma Multiforme)
Interventions: Other: Phlebotomy; Other: Phlebotomy
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012 - Conditions: Medulloblastoma,; Rhabdomyosarcoma,; Neuroblastoma,; Hepatoblastoma,; High Grade Glioma,; Astrocytoma
Intervention: Drug: LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Brain and Central Nervous System Tumors; Breast Cancer; Colorectal Cancer; Kidney Cancer; Lung Cancer; Melanoma (Skin); Ovarian Cancer; Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cediranib maleate; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Ependymoma; Brainstem Glioma; Astrocytoma; Glioblastoma Multiforme; PNET
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2011 - Condition: Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4
Intervention: Drug: Cilengitide
Sponsors: Northern Sydney and Central Coast Area Health Service; Northern Sydney and Central Coast Area Health Service; Merck KGaA
Recruiting - verified July 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012 - PI/II of Temozolomide & Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma MultiformConditions: Glioblastoma; Cancer of Brain and Nervous System; Glioblastoma Multiforme
Interventions: Drug: Temozolomide; Procedure: Stereotactic Radiosurgery
Sponsors: Stanford University; Stanford University
Recruiting - verified July 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Drug: temozolomide; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Grade IV Malignant Glioma; Glioblastoma Multiforme; Gliosarcoma
Intervention: Drug: AMG 102 plus Avastin (bevacizumab)
Sponsors: Duke University; Duke University; Amgen
Recruiting - verified April 2012 - Conditions: Glioblastoma; GBM; Glioblastoma Multiforme
Intervention: Drug: PF-00299804
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Henry Ford Hospital; Pfizer
Recruiting - verified April 2012 - Conditions: Brain Cancer; Glioblastoma Multiforme
Interventions: Drug: Vorinostat; Drug: Erlotinib; Drug: Temozolomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified February 2012 - Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Diffuse Astrocytoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Oligodendroglioma; Recurrent Adult Brain Tumor
Interventions: Drug: erlotinib hydrochloride; Drug: isotretinoin; Other: laboratory biomarker analysis; Genetic: protein expression analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Diffuse Intrinsic Pontine Glioma; Brainstem Glioma
Intervention:
Sponsors: Children's Research Institute; Children's Research Institute
Recruiting - verified April 2012 - Conditions: Solid Tumors; Glioblastoma Multiforme; Recurrent Malignant Gliomas
Interventions: Drug: CTO; Drug: CTO and Temodar-R
Sponsors: Tactical Therapeutics, Inc.; Tactical Therapeutics, Inc.
Recruiting - verified October 2011 - Condition: Brain Cancer
Intervention: Biological: HER.CAR CMV-specific CTL
Sponsors: Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine; Texas Children's Hospital
Recruiting - verified March 2012 - Condition: Glioblastomas
Interventions: Drug: Temozolomide; Drug: Bevacizumab; Radiation: Standard radiation therapy
Sponsors: Grupo Español de Investigación en Neurooncología; Grupo Español de Investigación en Neurooncología
Recruiting - verified January 2012 - Condition: Glioblastoma Multiforme
Intervention: Drug: Bevacizumab
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center; Genentech
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Intervention: Drug: AZD6244
Sponsors: Pediatric Brain Tumor Consortium; Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Meningioma; Anaplastic Oligodendroglioma; Brain Stem Glioma; Ependymoblastoma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Grade III Meningioma; Meningeal Hemangiopericytoma; Mixed Glioma; Pineal Gland Astrocytoma; Brain Tumor
Interventions: Biological: therapeutic allogeneic lymphocytes; Biological: aldesleukin; Other: laboratory biomarker analysis; Procedure: positron emission tomography
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified November 2011 - Conditions: Glioblastoma; Gliosarcoma; Brain Tumor
Interventions: Radiation: radiosurgery; Biological: bevacizumab; Drug: irinotecan hydrochloride
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified March 2012 - Conditions: Brain Cancer; Glioblastoma
Interventions: Drug: Standard Dose Bevacizumab; Drug: Low Dose Bevacizumab; Drug: Lomustine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Conditions: Brain Cancer; Brain Stem Tumors; Pontine Tumors
Intervention: Biological: Rindopepimut
Sponsors: Stanford University; Stanford University; National Institutes of Health (NIH); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: perifosine; Drug: temsirolimus; Genetic: fluorescence in situ hybridization; Genetic: western blotting; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2011 - Condition: Glioblastoma
Interventions: Radiation: radiotherapy; Drug: temozolomide
Sponsors: Centre Georges Francois Leclerc; Centre Georges Francois Leclerc; Ligue contre le cancer, France
Recruiting - verified November 2011 - Conditions: Adult Brain Tumor; Adult Brain Stem Glioma; Adult Diffuse Astrocytoma; Adult Ependymoma; Adult Grade II Meningioma; Adult Melanocytic Lesion; Adult Meningeal Hemangiopericytoma; Adult Mixed Glioma; Adult Oligodendroglioma; Adult Pineal Gland Astrocytoma; Adult Pineocytoma; Recurrent Adult Brain Tumor
Interventions: Radiation: proton beam radiation therapy; Procedure: quality-of-life assessment; Other: questionnaire administration
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Drug: temsirolimus; Genetic: DNA methylation analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Radiation: external beam radiation therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Recruiting - verified April 2010 - Condition: Brain Cancer
Intervention: Other: cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Children's Healthcare of Atlanta; Dana-Farber Cancer Institute; M.D. Anderson Cancer Center; Phoenix Children's Hospital; Alberta Children's Hospital; University of Colorado, Denver; Seattle Children's Hospital; Johns Hopkins University; Children's Mercy Hospital-Kansas City, MO; MD Anderson Cancer Center Orlando at Arnold Palmer Hospital for Children
Recruiting - verified March 2012 - Condition: Supratentorial Malignant Brain Tumor
Intervention: Biological: MR1-1
Sponsors: Duke University; Duke University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified December 2011 - Condition: Glioblastoma Multiforme
Intervention: Biological: autologous dendritic cells
Sponsors: Instituto Cientifico y Tecnologico de Navarra, Universidad de Navarra; Instituto Cientifico y Tecnologico de Navarra, Universidad de Navarra
Recruiting - verified November 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Genetic: DNA ploidy analysis; Genetic: fluorescence in situ hybridization; Genetic: microsatellite instability analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: diagnostic laboratory biomarker analysis; Other: flow cytometry; Other: immunohistochemistry staining method
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Genetic: fluorescence in situ hybridization; Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Other: immunohistochemistry staining method
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Glioblastoma Multiforme; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Mixed Oligoastrocytoma
Interventions: Drug: ZD6474; Drug: Carboplatin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: bortezomib + Temozolomide; Radiation: external beam radiation therapy
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cediranib maleate; Drug: cilengitide; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis; Procedure: magnetic resonance imaging
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Glioblastoma
Interventions: Procedure: Radiotherapy; Procedure: Radiotherapy; Drug: Temozolomide; Drug: BIBW2992; Drug: BIBW2992
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma
Intervention: Drug: Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012 - Conditions: Primary Glial Neoplasms of Brain; Glioblastoma
Interventions: Drug: Aminolevulinic Acid; Drug: Aminolevulinic Acid
Sponsors: West Penn Allegheny Health System; West Penn Allegheny Health System; DUSA Pharmaceuticals, Inc.
Recruiting - verified February 2010 - Condition: Glioblastoma Multiforme
Interventions: Device: Stealth Station; Device: PoleStar N20
Sponsors: Maastricht University Medical Center; Maastricht University Medical Center
Recruiting - verified July 2011 - Condition: Glioblastoma
Interventions: Drug: Temozolomide in both arms; Drug: Temozolomide in both arms
Sponsors: University of Heidelberg; Prof. Dr. Wolfgang Wick; Essex Pharma GmbH
Recruiting - verified October 2011 - Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Glioblastoma; Astrocytoma
Intervention: Drug: Bevacizumab/Irinotecan
Sponsors: Clinical Research Center for Solid Tumor, Korea; Clinical Research Center for Solid Tumor, Korea; Seoul National University Hospital
Recruiting - verified July 2011 - Conditions: Neurofibromatosis Type 1; Malignant Peripheral Nerve Sheath Tumor; Plexiform Neurofibroma; Optic Glioma; Neurofibroma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Conditions: Glioblastoma Multiforme; Malignant Gliomas; Anaplastic Gliomas
Intervention: Drug: Sutent (sunitinib)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Glioblastoma Multiforme
Interventions: Drug: bevacizumab [Avastin]; Drug: irinotecan; Drug: temozolomide
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device; Drug: Temozolomide
Sponsors: NovoCure Ltd.; NovoCure Ltd.
Recruiting - verified March 2012 - Condition: Glioblastoma
Intervention: Procedure: 18F]-FMISO PET-CT
Sponsors: University Hospital, Bordeaux; University Hospital, Bordeaux
Recruiting - verified April 2012 - Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: protein expression analysis; Other: diagnostic laboratory biomarker analysis; Other: immunohistochemistry staining method
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: anti-PDGFR alpha monoclonal antibody IMC-3G3; Biological: ramucirumab
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI); ImClone LLC
Recruiting - verified April 2012 - Conditions: Newly Diagnosed High-Grade Gliomas; Diffuse Intrinsic Pontine Glioma
Interventions: Drug: Temozolomide; Drug: Bevacizumab; Drug: Irinotecan
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati; Genentech
Recruiting - verified February 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: autologous CD133-positive BTSC mRNA-pulsed autologous dendritic cell vaccine; Procedure: adjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Duke University; Duke University; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: Glial Cell Tumors; Malignant Gliomas; Glioblastoma Multiforme; Anaplastic Astrocytoma; Gliomatosis Cerebri; Gliosarcoma; Brainstem Glioma
Interventions: Drug: Valproic acid; Drug: Bevacizumab; Radiation: Radiation therapy
Sponsors: Baylor College of Medicine; Baylor College of Medicine
Recruiting - verified February 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Recruiting - verified December 2011 - Conditions: Recurrent Glioblastoma Multiforme; Recurrent Gliosarcoma
Intervention: Drug: temozolomide and bevacizumab
Sponsors: Center for Neurosciences, Tucson; Center for Neurosciences, Tucson; Genentech
Recruiting - verified June 2011 - Condition: Brain Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Condition: Glioblastoma Multiforme/Anaplastic Astrocytoma
Interventions: Drug: temozolomide; Radiation: radiation therapy; Radiation: stereotactic radiotherapy
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center
Recruiting - verified November 2011 - Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Recurrent Adult Brain Tumor
Interventions: Drug: bendamustine hydrochloride; Procedure: quality-of-life assessment
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Comprehensive Cancer Network; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Low-grade Glioma; Astrocytoma; Oligodendroglioma; Mixed Oligoastrocytoma
Intervention: Drug: RAD001
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012 - Condition: Glioblastoma
Interventions: Drug: Sirolimus; Drug: Vandetanib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Brigham and Women's Hospital; Dana-Farber Cancer Institute; AstraZeneca
Recruiting - verified April 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: lymphokine-activated killer cells; Drug: polifeprosan 20 with carmustine implant
Sponsors: National Cancer Institute (NCI); Hoag Cancer Institute at Hoag Memorial Hospital Presbyterian
Recruiting - verified June 2009 - Condition: Brain and Central Nervous System Tumors
Intervention: Drug: aminolevulinic acid
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Mixed Oligoastrocytoma; Malignant Astrocytoma NOS
Intervention: Drug: Nanoliposomal CPT-11
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2012 - Conditions: Mixed Gliomas; Malignant Gliomas; Glioblastoma Multiforme
Interventions: Drug: XL765 (SAR245409); Drug: Temozolomide
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Glioblastoma
Intervention: Drug: nelfinavir
Sponsors: Maastricht Radiation Oncology; Maastricht Radiation Oncology; Maastricht University Medical Center
Recruiting - verified April 2012 - Condition: Glioblastoma
Intervention: Drug: bsi-201 plus temozolomide
Sponsors: Sanofi-Aventis; Sanofi-Aventis; BiPar Sciences
Recruiting - verified June 2011 - Condition: Malignant Gliomas
Interventions: Drug: Irinotecan; Drug: Lenalidomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified January 2012 - Conditions: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma
Interventions: Drug: temozolomide; Drug: carmustine; Radiation: radiation therapy; Procedure: autologous hematopoietic stem cell transplantation; Drug: O6-benzylguanine; Biological: filgrastim; Procedure: in vitro-treated peripheral blood stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Diagnostic Imaging
Intervention: Drug: Ferumoxytol
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Solid Tumor; Adult Central Nervous System Germ Cell Tumor; Adult Rhabdomyosarcoma; Childhood Central Nervous System Germ Cell Tumor; Childhood Soft Tissue Sarcoma; Ewing Sarcoma; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Ovarian Mixed Germ Cell Tumor; Previously Untreated Childhood Rhabdomyosarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway and Hypothalamic Glioma; Recurrent Childhood Visual Pathway Glioma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Neuroblastoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: busulfan; Drug: melphalan; Drug: topotecan hydrochloride; Other: laboratory biomarker analysis; Biological: filgrastim; Procedure: autologous hematopoietic stem cell transplantation; Other: pharmacological study; Procedure: autologous bone marrow transplantation
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified November 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Genetic: DNA methylation analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group; Radiation Therapy Oncology Group; Medical Research Council; Cooperative Trials Group for Neuro-Oncology
Recruiting - verified May 2011 - Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Liver Cancer; Retinoblastoma; Sarcoma
Interventions: Biological: filgrastim; Drug: busulfan; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: thiotepa; Procedure: stem cell transplantation; Procedure: positron emission tomography; Radiation: tomotherapy; Radiation: total marrow irradiation; Drug: Mesna; Radiation: Whole lung radiation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified July 2011 - Condition: Recurrent Glioblastoma
Interventions: Drug: enzastaurin; Drug: bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Genentech
Recruiting - verified October 2011 - Conditions: Glioblastoma Multiforme; Anaplastic Glioma
Interventions: Drug: Vorinostat; Drug: Isotretinoin; Procedure: Surgical Resection; Drug: Temozolomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified March 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: motexafin gadolinium; Drug: temozolomide; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Cancer and Leukaemia Group
Recruiting - verified June 2009 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Genetic: DNA methylation analysis; Procedure: quality-of-life assessment; Radiation: Radiation
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; European Organization for Research and Treatment of Cancer - EORTC; Trans-Tasman Radiation Oncology Group (TROG)
Recruiting - verified March 2012 - Conditions: Recurrent Anaplastic Astrocytoma; Recurrent Anaplastic Oligodendroglioma; Recurrent Anaplastic Oligo-Astrocytoma; Recurrent Glioblastoma Multiforme
Intervention: Drug: Topotecan
Sponsors: Columbia University; Columbia University; National Cancer Institute (NCI); Herbert Irving Comprehensive Cancer Center
Recruiting - verified December 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: carcinoembryonic antigen-expressing measles virus; Genetic: fluorescence in situ hybridization; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: needle biopsy; Procedure: neoadjuvant therapy
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: imatinib mesylate; Drug: temozolomide; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2007 - Conditions: Renal Cell Carcinoma; Neuroendocrine Tumours
Intervention: Drug: 18F-FAZA PET Imaging
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified March 2012 - Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma
Intervention: Drug: Erlotinib
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; Genentech
Recruiting - verified March 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: arsenic trioxide; Drug: temozolomide; Radiation: radiation therapy
Sponsors: Northwestern University; Northwestern University; Cephalon; Cell Therapeutics
Recruiting - verified May 2012 - Conditions: Brain and Central Nervous System Tumors; Lymphoma; Metastatic Cancer
Intervention: Drug: Melphalan
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Brain Tumor, Recurrent; Glioblastoma Multiforme
Intervention: Procedure: Photon Radiosurgery System (Intrabeam)
Sponsors: Children's Memorial Hospital; Children's Memorial Hospital; Photoelectron Corporation
Recruiting - verified April 2012 - Conditions: Glioblastoma; Recurrent Metastatic Cancer to the Brain
Intervention: Device: ExAblate 3000
Sponsors: InSightec; InSightec
Not yet recruiting - verified March 2012 - Condition: Glioblastoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Brain and Central Nervous System Tumors; Thrombocytopenia
Interventions: Drug: Carboplatin; Drug: Cyclophosphamide; Drug: Etoposide phosphate; Drug: Etoposide; Drug: Sodium thiosulfate
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Neurologic Disorders
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified January 2012 - Conditions: Glioblastoma Multiforme; Glioblastoma; GBM; Grade IV Astrocytoma; Glioma; Brain Cancer; Brain Tumor
Intervention: Drug: Dendritic cell immunotherapy
Sponsors: Northwest Biotherapeutics; Northwest Biotherapeutics
Recruiting - verified May 2012 - Conditions: Astrocytoma; Central Nervous System Tumor; Glioblastoma; Glioma; Medulloblastoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Brain and Central Nervous System Tumors; Metastatic Cancer
Interventions: Drug: verteporfin; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Medical College of Wisconsin
Recruiting - verified June 2009
 |
Join Clinical Trials That Study Astrocytomas |
